Life sciences counsel Beth Weinman (Washington, D.C.) discussed U.S. Food & Drug Administration enforcement priorities and qui tam whistleblower lawsuits in a Nov. 13 article published in Medtech Insight.
Ms. Weinman, who previously served as associate chief counsel for enforcement at the FDA’s Office of Chief Counsel, addressed topics including what leads someone to file a whistleblower complaint against a medical device company, and how companies should respond if a qui tam suit is filed against it, among other issues.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.